Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Richen Europe is a medical technology company specializing in the diagnosis of gastroenterological conditions, particularly Helicobacter pylori infections. As the European subsidiary of the Richen Group, the company provides non-invasive 13C-Urea Breath Test (UBT) systems, including both the diagnostic reagents and the infrared spectrometers required for analysis. Their products are widely used in clinical settings for the rapid and accurate detection of H. pylori, which is a primary cause of gastritis and peptic ulcers. Richen Europe focuses on the distribution, technical support, and regulatory compliance of these diagnostic solutions across the European market. The company's portfolio is centered on providing high-sensitivity, non-radioactive diagnostic tools that improve patient comfort and clinical efficiency.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Richen Europe.